Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An Optimized, Synthetic DNA Vaccine Encoding the Toxin A and Toxin B Receptor Binding Domains of Clostridium difficile Induces Protective Antibody Responses In Vivo

15 Jul 2014

Abstract excerpt

Clostridium difficile-associated disease (CDAD) constitutes a large majority of nosocomial diarrhea cases in industrialized nations and is mediated by the effects of two secreted toxins, toxin A (TcdA) and toxin B (TcdB). Patients who develop strong antitoxin antibody responses can clear C. difficile infection and remain disease free. Key toxin-neutralizing epitopes have been found within the carboxy-terminal...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clostridium difficile and Clostridium perfringens research
Share to Microscopic Colitis
Share to Viral gastroenteritis research and epidemiology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25024365
DOI: 10.1128/iai.01950-14

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An Optimized, Synthetic DNA Vaccine Encoding the Toxin A and Toxin B Receptor Binding Domains of Clostridium difficile Induces Protective Antibody Responses In VivoPMID 25024365Read ↗

A DNA vaccine targeting TcdA and TcdB induces protective immunity against Clostridium difficileSemantic proximity Read ↗

Nanobodies against C. difficile TcdA and TcdB reveal unexpected neutralizing epitopes and provide a toolkit for toxin quantitation in vivoSemantic proximity Read ↗

A novel approach to generate a recombinant toxoid vaccine against Clostridium difficile.Semantic proximity Read ↗

Application of recombinant antibodies for treatment of Clostridioides difficile infection: Current status and future perspectiveSemantic proximity Read ↗

Selection of Nanobodies that Block the Enzymatic and Cytotoxic Activities of the Binary Clostridium Difficile Toxin CDTSemantic proximity Read ↗

Broad Coverage of Genetically Diverse Strains of Clostridium difficile by Actoxumab and Bezlotoxumab Predicted by <i>In Vitro</i> Neutralization and Epitope ModelingSemantic proximity Read ↗

A Modified R-Type Bacteriocin Specifically Targeting Clostridium difficile Prevents Colonization of Mice without Affecting Gut Microbiota DiversitySemantic proximity Read ↗

An Update on Clostridioides difficile Binary ToxinSemantic proximity Read ↗

Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab.Semantic proximity Read ↗

Selection and characterization of ultrahigh potency designed ankyrin repeat protein inhibitors of C. difficile toxin BSemantic proximity Read ↗

Development of a Novel Vaccine Containing Binary Toxin for the Prevention of Clostridium difficile Disease with Enhanced Efficacy against NAP1 StrainsSemantic proximity Read ↗

Phylogenomics of 8,839 Clostridioides difficile genomes reveals recombination-driven evolution and diversification of toxin A and B.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.